Sanofi, Regeneron See Positive Results From Dupixent Phase 3 Trial

Date : 23/05/2020 @ 09:34
Source : Dow Jones News
Stock : Regeneron Pharmaceuticals Inc (REGN)
Quote : 569.91  0.0 (0.00%) @ 22:22
Regeneron Pharmaceuticals share price Chart
Pre-Market
Last Trade
Last $ 549.50 ▼ -20.41 (-3.58%)

Sanofi, Regeneron See Positive Results From Dupixent Phase 3 Trial

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart


From Apr 2020 to May 2020

Click Here for more Regeneron Pharmaceuticals Charts.

By Kimberly Chin

 

Sanofi SA and Regeneron Pharmaceuticals Inc. said it had positive results for an advanced trial of a treatment for patients with a chronic, allergic inflammatory disease of the esophagus.

The Phase 3 trial of Dupixent met both its co-primary endpoints, as well as important secondary endpoints, the companies said. The trial had 81 patients, ages 12 years and older, who had eosinophilic esophagitis.

The patients were able to show clinical and anatomic improvements, including the ability to swallow. Patients saw a 69% reduction in disease symptoms, as well as a 60% reduction in their esophageal eosinophilic count to a normal range, the companies said.

Eosinophilic esophagitis damages the esophagus and impairs its functions, making it difficult to swallow. It could also damage and scar the esophagus without treatment.

This was the first and only biologic to show "positive and clinically meaningful results" in an advanced trial, the companies said.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

(END) Dow Jones Newswires

May 22, 2020 19:19 ET (23:19 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Your Recent History
FX
EURAUD
Euro vs Au..
FX
USDAUD
US Dollar ..
ASX
WPL
Woodside
NASDAQ
AAPL
Apple
ASX
BHP
BHP Bilito..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20200526 12:38:23